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1. Introduction  
Human papillomavirus (HPV) is a DNA virus which belongs to the newly named 
Papillomaviridae family (de Villiers et al., 2004). The papillomaviruses induce a variety of 
proliferative lesions in the skin and internal mucosa. Nearly half of the over 200 types of 
HPVs can infect the genital mucosa, producing benign epithelial lesions. However, a subset 
of these viruses is found in over 90% of malignant carcinomas of the genital tract, the 
majority of which contain the HPV16 and 18 types considered to be of "High Risk" (HR), as 
they help the progression into cervical cancer (Lorincz et al., 1992; Shah & Buscema, 1988). 
The mechanisms through which HPVs induce cell transformation have been intensively 
investigated in the last few years. The most abundant viral transcripts in tumor and tumor 
cell lines are produced from the E6 and E7 Open Reading Frames (ORFs) that are known to 
be oncogenic. These two genes from HPV are necessary and sufficient to induce HPV-
mediated transformation of murine cells (Yasumoto et al., 1986), transform human 
fibroblasts (Pirisi et al., 1987), and in cooperation with ras are capable of transforming baby 
rat kidney cells (Phelps et al., 1988) and primary human keratinocytes (Yoshida et al., 2008). 
The best evidence for the role of E6 and E7 proteins in malignancy comes from biochemical 
studies. E6 and E7 oncoproteins from the HR-HPV types have the ability to alter pathways 
involved in cell cycle control, interacting with and neutralizing the regulatory function of 
primarily two suppressor proteins, p53 and pRb respectively (Dyson et al., 1992; Werness et 
al., 1990). These effects produce genetic instability and accumulation of mutations that 
might contribute to the oncogenic process. Besides, several other target proteins for E6 and 
E7 oncoproteins have been identified and probably those interactions also promote cellular 
transformation. The latest oncogene identified from HPV was the E5 from HPV16. The E5 
oncoprotein showed to be capable of increasing the half-life of Epidermal Growth Factor 
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(EGF) and Platelet-Derived Growth Factor (PDGF) receptors (Leechanachai et al., 1992). 
Contrary to E6 and E7, the E5 oncogene is lost in the late stages of cervical cancer due to 
viral integration to the cellular genome. However, the close association with growth factor 
receptors could suggest that E5 has a key role in viral life cycle and may have an important 
function in the early development of the neoplasia. 
The oncogenes mentioned above codify for oncoproteins that have developed a plethora of 
strategies resulting in the alteration of cell cycle and apoptosis control by targeting the same 
or different cellular pathways, favoring viral persistence and leading to a strong synergism 
in promoting cellular transformation. Several studies have been performed to elucidate the 
mechanisms through which these HPV oncogenes allow the cellular transformation and the 
generation of the cervical cancer. Recently, the development of genomic and proteomic 
techniques has promoted the research of cervical cancer progression due to HPV infection, 
allowing the identification of protein interaction networks and the discovery of biomarkers 
useful for diagnostic and therapeutic systems. 
2. Organization and classification of human papillomaviruses 
HPV is a non enveloped DNA virus with icosahedral capsid that surrounds one copy of 
circular double stranded DNA close to 8 kb long. HPV genome codes for eight proteins 
classified as early (E) and late (L) proteins expressed from polycistronic mRNA by a positive 
DNA strand. Between E and L coding sequences is a Long Control Region (LCR) that has 
low conservation among members of the Papillomaviridae family. This region promotes and 
enhances the viral gene expression and it does not include ORFs (de Villiers et al., 2004; 
Syrjänen & Syrjänen, 1999). The HPVs maintain high fidelity of their genome as they use the 
host cell proofreading polymerases, generating mutations at similar rates as the host DNA 
genome. HPVs involve different genotypes, defined as a complete cloned genome whose L1 
ORF most conserved segment has a DNA sequence at least 10% different from any other 
HPV type (Bernard, 2005; de Villiers et al., 2004; Myers et al., 1996). HPV subtypes may be 
found (differences between 2-10% of homology) like HPV55 that is a subtype of HPV44. The 
HPV variants are defined as those that show differences of less than 2% of homology in 
nucleotide sequence in the coding regions and 5% in the non-coding regions from the 
original isolate (prototype) (Bernard et al., 1994; Bernard, 2005; de Villiers et al., 2004). Now 
at days, more than 200 suggested types have been detected and 100 types have been 
completely sequenced, all of them registered at the German Cancer Research Center in 
Heidelberg, Germany (Bernard, 2005; de Villiers et al., 2004). 
All HPV types are epitheliotropic and may be found in mucous tissue and/or in skin (de 
Villiers, 1989; Myers et al., 1996). Recently, the new taxonomy of papillomaviruses grouped 
them in 16 higher-order cluster groups (super-groups or major branches) named genus 
which share from 23 to 43% of identity. The genera are identified by Greek letters (alpha to 
pi) and divided in lower-order clusters named species that share 60-70% of identity within a 
genus and 71-89% within a species (de Villiers et al., 2004). Species are identified by 
numbers and group HPV types with common phylogenetical, biological and pathological 
properties (Bernard, 2005; de Villiers et al., 2004). HPVs are classified into five genera (alpha, 
beta, gamma, mu and nu) (Bernard et al., 2010). The alpha-papillomavirus genus contains all 
the clinically important HPVs associated with mucosal and genital lesions. While, the beta-
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papillomavirus genus includes all cutaneous HPV types involved in Epidermodysplasia 
verruciformis or skin cancer in immunosupressed subjects, the gamma-papillomavirus genus 
includes cutaneous HPV types distinguished by intracytoplasmic inclusion bodies in 
histological tests (Bernard, 2005; de Villiers, 1989; de Villiers et al., 2004). 
There are a limited number of variants for each HPV type, some of which are highly 
divergent, especially those taken from ethnic groups that evolved without geographical 
contact. Thus, it seems that each HPV type was not transferred from other species, has been 
with the human race since its origins, evolved together and spread as human ethnic groups 
arose and populated the world (Bernard, 2005). The HPV16 variants can be divided into six 
geographically clustered phylogenetic groups, the European (E), African 1 and 2 (Af1 and 
Af2, respectively), Asian (As), Asian-American (AA) and North American (NA) (Yamada et 
al., 1997). Clinically speaking, there is an interesting concern on the biological activity of 
HPV variants because some of them are more frequently detected (94%) in high-grade 
cervical lesions than the HPV16 prototype (6%) (Zehbe et al., 1998) and being associated to 
the development of cervical lesions grade 2-3 (Xi et al., 2002). However, more 
epidemiological and laboratory studies need to be performed to confirm these observations. 
Bravo and Alonso suggested an alternative classification system based on the nucleotide 
sequence of the E1 and E2 ORFs. Also, they proposed that concatenated E1-E2 proteins 
sequences can be incorporated as a suitable evolutionary standard for Papillomaviridae 
classification (Bravo & Alonso, 2007). Due to the increasing number of new sequences of 
Papillomaviruses (PVs), Bernard and coworkers proposed the expansion of the family 
Papillomaviridae. To accomplish this, the names of genera were extended to the end of the 
Greek alphabet (from Alphapapillomavirus to Omegapapillomavirus), followed by the prefix 
“Dyo” (i.e., “a second time”), omitting the designation from Dyoalphapapillomavirus to 
Dyogammapapillomavirus because the Alpha, Beta and Gamma genera include the most 
common and medically important HPVs. Also, they named the rest of PVs genera waiting 
for classification as Rho to Omega, assigning the terms “Dyodelta-PVs”, “Dyoepsilon-PVs” and 
so on, for the new PV genus (Bernard et al., 2010). 
Phylogenetical analysis of the E5, E6 and E7 gene sequences have revealed that only E6 and 
E7 genes from the alpha genus are highly conserved (>75% and >65% homology, 
respectively). However, when only the HR-HPV types of the alpha genus are considered the 
homologies go up to 80% for E6 and up to 70% for E7 sequences. The less conserved viral 
sequences from the alpha genus are those from the E5 gene, since the homology in this 
genus is only of 25% and 40% when only the HR-HPV types are considered. Few years ago, 
Bravo and Alonso (2004) described the evolutionary characteristics of the E5 proteins and 
compared them with the E6 and E7 oncogenic proteins and with the structural proteins L1 
and L2. They showed that there is a clear pattern of divergence from late to early genes at 
the protein level, which increased in the progression L1 < L2 < E6 ≈ E7 < E5. Among the E5 
proteins from the alpha genus it was clear that there was not an evident sequence similarity 
and that the evolutionary divergence between present proteins rises to 80% (Bravo & 
Alonso, 2004). The few common characteristics for the alpha genus E5 proteins are the high 
hydrophobicity, the high Ile+Leu+Val content and the presence of transmembranal regions. 
Taking into consideration these characteristics of the E5 protein, Bravo and Alonso (2004) 
identified 4 groups of E5 proteins in the alpha genus (E5ǂ, E5ǃ, E5Ǆ and E5ǅ) and proposed 
that besides of the phylogenetic characteristics, the chemical part of the proteins have to be 
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taken into consideration to have a more specific classification, as it has been suggested that 
the protein chemistry is an important restriction for protein evolution (Babbit & Gerlt, 1997).  
On the other hand, Wang and coworkers (2010) showed that the Canine Papillomavirus 
type 2 (CPV2) encodes an E7 protein that has Ser substituted for Cys at the LXCXE motif, 
important in the E7 proteins from the alpha genus, to bind and degrade the pRb protein. 
This mutation in the CVP2 E7 protein abrogates pRb binding at this site; however a new 
domain with a binding site for pRb was identified at the C-terminal region of canine E7, and 
was able to degrade the pRb protein. At the same time, these researchers demonstrated that 
the HPV4 E7 protein also binds pRb in a similar way as CPV2 E7 protein and by screening 
of HPV genome sequences identified that the LXSXE motif of the CPV2 E7 protein was also 
present in the gamma HPV genus (Wang et al., 2010).  
Altogether these data show that phylogenetic sequence analysis is important to trace the 
papillomaviruses evolution and define ancestors, but also showed that when chemical and 
biological characteristics of the oncogenic HPV proteins are integrated into the analysis, 
there is a better classification of HPVs within the genus, as subgroups were identified. 
However, more work needs to be done before this type of integrative analysis can be used to 
give some light between clinical manifestations and the development of cancer associated to 
HPV. 
3. Viral cycle and HPV integration into the genome of host cell 
During HPV infection, the different viral proteins are expressed sequentially (Middleton et 
al., 2003; Peh et al., 2002). The HPV infection starts in the basal cell layer of the cervix since 
these cells express the specific receptors for viral entry and also because are the only cells in 
the squamous epithelium capable of dividing. Molecules like heparan sulfate and 
glycosaminoglycans seem to mediate the attachment of the virions via interaction of the 
major capsid protein, L1, to the basal membrane of human keratinocytes. The internalization 
of some HPV types is a slow process mediated by clathrin-coated vesicles, or the caveolae-
dependent route (Bousarghin et al., 2003; Horvath et al., 2010). Once the virus has 
penetrated the cell, disassembly of HPV particles occurs in cytoplasmic vesicles, followed by 
the delivery of the viral DNA into the nucleus mediated by L2 (Day et al., 2004). After 
infection, HPV genomes are established as autonomous replicating extra-chromosomal 
elements or episomes and start a low expression level of the E6 and E7 genes (Middleton et 
al., 2003; Moody & Laimins, 2010). The E6 and E7 gene expression is achieved by cellular 
transcription factors that interact with the LCR, a region where the E2 protein interacts to 
repress or to activate viral transcription. The promoter region from HPVs contains TATA 
boxes for binding cellular transcriptional factors like TFIID and an epithelial cell-specific 
enhancer, which holds binding sites for transcription factors like Sp-1 and AP-1, among 
others (Butz & Hoppe-Seyler, 1993; Doorbar, 2005; Middleton et al., 2003; Tan et al., 1994). 
The expression of E6 leads mainly to the ubiquitin-dependent proteolysis of p53 (Farthing & 
Vousden, 1994; Münger et al., 1992; Rapp & Chen, 1998), preventing cell growth inhibition 
in both undifferentiated and differentiated cells (Moody & Laimins, 2010) and the E7 
expression to the liberation of the transcription factor E2F by sequestration of pRb (Münger 
et al., 1992), effects that promote cellular proliferation and genome instability throughout 
the infected tissue. 
www.intechopen.com
Molecular Bases of Human Papillomavirus 
Pathogenesis in the Development of Cervical Cancer 253 
While the basal HPV infected cell migrates to upper layers and differentiates, the viral cycle 
continues with the E1, E2, E4 and E5 protein expression and viral DNA replication (Doorbar, 
2005; Longworth & Laimins, 2004; Middleton et al., 2003; Peh et al., 2002). First, the E1 
protein hexamerizes to recruit the cellular DNA polymerase and replication accessory 
proteins, while it displaces Histone H1 and functions as a helicase/ATPase to start the viral 
genome replication (Hughes & Romanos, 1993; Lambert, 1991; Swindle & Engler, 1998). It 
has been observed that the E1 and E2 expression is auto-regulated and activated by 
replication. The E2 protein modulates E1 expression and E6 splicing differentially regulates 
E1 and E2 expression (Hubert & Laimins, 2002). Once the viral replication has finished, E2 
levels raise and repress the E6 and E7 expression by binding to the HPV early promoter as a 
dimmer and promoting the liberation of cellular transcriptional activator factors (Tan et al., 
1994).  
On the other hand, the E4 protein is translated from a spliced E1^E4 transcript to form a 
fusion protein that contains the first 5 amino acids (aa) from the E1 protein and the E4 ORF. 
In warts, E4 exists as multiple species that are formed from a combination of progressive 
proteolysis of the N-terminal residues, oligomerization, and phosphorylation. The species 
resulting from proteolysis are the 17 kDa species in the parabasal cell layer of epithelium 
and this is coincident with viral genome amplification. The E4 16, 11 and 10 kDa species are 
accumulated in superficial keratinocytes, where capsid proteins expression and assembly 
occurs (Doorbar et al., 1988; Middleton et al., 2003). It is known that E4 binds to zinc, 
cytoskeleton and cytokeratins (Roberts et al., 1994; Wang et al., 2004). Therefore, it is 
suggested that E4 may alter the normal keratinization process to benefit the viral cycle 
progress and generate a cytoskeleton collapse (Gaillard et al., 1992) inducing apoptosis 
through alteration of mitochondrial function (Raj et al., 2004) and favoring the viral particle 
liberation (Gaillard et al., 1992). However, in natural infections only a limited amount of 
keratin collapse has been observed (Doorbar et al., 1996). The E4 protein sequesters the 
CDK1/Cyc B1 complex (CDK, Cyclin dependent kinase and Cyc, Cyclin) onto the 
cytokeratin network, preventing their nuclear accumulation and therefore inducing 
inhibition of the G2/M transition of the cell cycle (Davy et al., 2002; Nakahara et al., 2002) 
and allowing viral and genomic DNA replication. The HPV16 E4 coding region possesses a 
splicing enhancer element required for the early viral mRNA splicing (Rush et al., 2005), 
especially for the expression of late viral transcripts of E1^E2, E1, E4 and E5, thus regulating 
the viral DNA amplification (Wilson et al., 2005). 
Other protein suggested to be expressed at the same time as E4 is E5, both of which may 
contribute to viral genome amplification (Doorbar, 2006; Syrjänen & Syrjänen, 1999). A 
polycistronic mRNA containing the E5 sequence is the most abundant transcript in HPV 
positive cervical carcinomas in situ (Stoler et al., 1992). E5 transcripts expression is very low 
in undifferentiated cells (Reagan & Laimins, 2008). The E5 mRNA and protein are mainly 
present in the lower third of the epithelium of Low Grade Squamous Intraepithelial Lesions 
(LSILs), and might contribute to neoplastic proliferation during the early stages of infection 
(Chang et al., 2001; Stoler et al., 1992), or to be essential for malignant transformation 
(Stoppler et al., 1996). The gene encoding the viral E5 protein is frequently disrupted or lost 
when viral DNA is integrated into human genome (Pater & Pater, 1985). Even though, E5 
protein expression pattern in cervical epithelia has not been accomplished yet, it has been 
observed that E5 function is needed to maintain the cell proliferation stimuli driven by the 
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EGF Receptor (EGFR) signaling pathway at this stage (Syrjänen & Syrjänen, 1999). In this 
way, the E5 function complements the E7 and E6 functions, to generate and maintain the 
transformed phenotype (Stöppler et al., 1996). 
A special characteristic of the viral cycle is that the last stages take place in terminally 
differentiated keratinocytes (Schiller et al., 2010). In this stage, viral particles are generated 
when the expression of capsid proteins (L1 and L2) starts by a promoter localized in the late 
region of the HPV genome. The L1 and L2 proteins polymerize into icosahedral capsids in a 
thermodynamic stable and spontaneous process that involves the binding of the HPV DNA to 
the N-terminal sequence of the L2 protein (Hagensee et al., 1993; Zhou et al., 1994). During 
their formation, HPV capsids require maturation (formation of intermolecular disulfide bonds 
in L1), event that leads to stability and virions liberation in the external surface of the 
squamous epithelium by cellular death (Buck et al., 2005; Syrjänen & Syrjänen, 1999). Up to 
now, it is still unknown if encapsidation of the viral genome takes place during or after capsid 
assembly (Conway & Meyers, 2009; Holmgren et al., 2005), but it has been suggested that L2 
uses E2 to recruit the viral genome to the site of virion assembly (Holmgren et al., 2005). 
During HPV productive infections that lead to cervical lesions, the viral genome is episomal 
with a great copy number that depends on differentiated cells. Throughout the HPV 
persistent infection, there is a gradual deregulation in the expression of E6 and E7 proteins 
that may lead to the development of low-grade cervical lesions, where one third of the 
epithelium is formed by E6/E7 expressing basal cells. The progression from High Grade 
Squamous Intraepithelial Lesions (HSILs) to cancer usually occurs in lesions that contain 
integrated copies of the viral genome. This event leads to an abortive infection (Farthing & 
Vousden, 1994; Münger et al., 2004; Peitsaro et al., 2002) and cells cannot longer produce 
new viral particles (Matlashewski, 2006). It has been observed that the viral integration 
occurs mainly between E1-E2 ORFs, event that produces the loss of E2 and E4 genes 
expression. Thus, the loss of E2 and E4 genes generates a down-replication of the viral 
genome, G2 arrest, and E6 and E7 over-expression (Jeon & Lambert, 1995; Wilson et al., 
2005). Thus, the integration of the HPV DNA in the host genome represents an important 
event in cervical carcinogenesis (Pett & Coleman, 2007), as this may cause cellular 
immortalization (Band et al., 1990; Jeon & Lambert, 1995; Münger et al., 1992; zur Hausen, 
2000), reduction of cellular differentiation, cellular dysplasia and TNF-α non-responder cells 
(TNF, Tumor Necrosis Factor) (Syrjänen & Syrjänen, 1999; zur Hausen, 2000).  
Besides increasing the transcript stability and protein expression of the viral E6 and E7 
oncoproteins, integration of the viral genome may cause chromosomal rearrangements (Jeon & 
Lambert, 1995) and influences cancer progression through interaction with hTERT, p53 and 
pRB (Raibould et al., 2011). The integration of HPV sequences in the host genome occurs 
randomly, although in invasive genital carcinomas or cervical cancer-derived cell lines, HPV 
genome has been found frequently integrated near fragile sites, like translocation breakpoints 
(Koopman et al., 1999; Mammas et al., 2008), or modifying proto-oncogenes sequences either 
by rearrangement or amplification as has been observed for myc genes (Ocadiz et al., 1987; 
Sastre-Garau et al., 2000). Disruption or deregulation of defined critical cellular gene functions 
by insertional mutagenesis of HPV genome fragments has been hypothesized as the major 
promoting factor in the pathogenesis of HPV-associated cancers (Wentzensen et al., 2004). 
Further investigation on early integration events needs to be done to describe the mechanism 
by which viral infection is aborted and cell transformation is generated. 
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4. Role and function of HPV oncoproteins 
4.1 E5 oncoprotein 
4.1.1 E5 biochemical properties 
The E5 oncoproteins are small highly hydrophobic proteins important in the carcinogenic 
process and recently have been identified as potential oncogenes, although their role is not 
well understood (Bouvard et al., 1994). The E5 proteins from both animal and human 
sources can transform mammalian cells with different degrees of efficiency (Bouvard et al., 
1994; Horwitz et al., 1989; Straight et al., 1993). Both BPV-1 (bovine papillomavirus) and 
HPV E5 proteins are transmembrane proteins localized in Golgi and endosomes, but they 
have also been found in plasmatic membrane and endoplasmic reticulum (ER) (Cartin & 
Alonso, 2003; Conrad et al., 1993; Disbrow et al., 2005; Lewis et al., 2008). The E5 
oncoprotein from HPV16 has 83 aa residues with an estimated molecular weight of 10 kDa. 
The E5 protein presents three transmembranal helices and short hydrophilic regions at the 
C- and N-terminus (Alonso & Reed, 2002; Ullman et al., 1994; Yang et al., 2003), being the 
first hydrophobic region important for cellular localization of E5 (Fig. 1) (Cortese et al., 2010; 
Lewis et al., 2008). In HaCat cells (immortalized human keratinocytes) this region confers 
anchorage-independent growth and is associated with the capacity of these cells to invade 
extracellular matrix in organotypic “raft” assays (Barbaresi et al., 2010; Lewis et al., 2008).  
It has been demonstrated that E5 proteins contribute to cellular transformation by  
increasing the mitogenic signal from growth factor receptors to the nucleus (Leechanachai et 
al., 1992).  
4.1.2 E5 functional properties 
A proposed mechanism for E5 transforming activity is through increasing the half-life of the 
tyrosine kinase-containing growth factor receptors like EGFR, the phosphorylation state of 
this receptor or both (Genther-Williams et al., 2005; Straight et al., 1993, 1995; Tomakidi et 
al., 2000). It has been also proposed that HPV E5 proteins interact with the 16 kDa subunit of 
the protonic ATPase, inhibiting the acidification of endosomes and retarding the receptor 
degradation (Andresson et al., 1995; Briggs et al., 2001; Conrad et al., 1993; Straight et al., 
1995). At the same time, E5 induces a number of functional effects like causing alkalinization 
of endocellular pH, tyrosinase activation, melanin deposition and modulation of sensitivity 
to dopamine mimetic drugs as it has been shown in melanocytes that express E5 from 
HPV16 (Di Domenico et al., 2009). The second and third transmembranal domains cooperate 
to bind the protonic ATPase-16 kDa subunit (Adam et al., 2000; Rodriguez et al., 2000). 
However, some contradictory studies indicate that E5 proteins bind, but do not disturb the 
activity of the vacuolar protonic ATPase (Adam et al., 2000; Ashby et al., 2001; Rodriguez et 
al., 2000), and it has been shown that the final effect is due to a perturbation of the endocytic 
trafficking (S.L. Chen et al., 1996c). In contrast, it has been demonstrated that HPV16 E5 
stimulates the EGFR-mediated signal transduction by inhibiting the interaction with c-Cbl 
and decreasing the receptor degradation pathway (B. Zhang et al., 2005a) (Fig. 2). Recently, 
it was shown that HPV16 E5 down-modulates the KGFR/FGFR2b (keratinocyte growth 
factor receptor) by interference of the endocytic receptor pathway and perturbing the 
differentiation process (Belleudi et al., 2011). 
www.intechopen.com
Human Papillomavirus and Related Diseases 
– From Bench to Bedside – Research Aspects 256 
 
Fig. 1. Biochemical characteristics of the HPV16 E5 oncoprotein. (A) The E5 protein with 83 
amino acid residues has an estimated molecular weight of 10 kDa. (B) E5 is divided in three 
hydrophobic regions as estimated by the Kyte-Doolittle Hydropathy Plot.  (C) The first 
region (aa 1-30) is important for membrane localization and for anchorage-independent 
growth. The second (aa 41-54) and third (aa 54-78) hydrophobic regions contain the domains 
for binding to the protonic ATPase-16 kDa subunit. 
The expression of E5 protein has been associated with the expression of other members of 
the EGFR family (i.e. ErbB1, ErbB4) as well as the activity of ErbB2 (Crusius et al., 1998) and 
components of the EGF signaling pathway, like MAPKs (ERK1/2) (Crusius et al., 1997; S.H. 
Kim et al., 2006). The activation of members of the MAPK pathway may lead to regulation 
of other set of genes implicated in growth, as was observed that HPV16 E5 favors the over-
expression of transcriptional factors such as c-Fos and c-Jun that form the AP-1 complex 
(S.L. Chen et al., 1995, 1996a, 1996b), and stimulates transcription of genes involved in cell 
growth. During the cell cycle the E5 proteins from HPV11 and 16 have shown to be able to 
modulate cell proliferation, due to repression of p21Waf1 gene expression through c-jun 
activation (Tsao et al., 1996). In addition, our laboratory has identified that HPV16 E5 
increases the down-regulation of p27Kip1 CDK inhibitor in an EGFR dependent pathway, 
allowing the cells to stay for longer time into the cell cycle due to an increment in the S-
phase (Pedroza-Saavedra et al., 2010) (Fig. 2). Also, HPV16 E5 is able to activate other type 
of transcriptional factors like NF-κB and leading to COX-2 expression (S.H. Kim et al., 2009) 
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(Fig. 2). More recently, it has been suggested that HPV16 E5 protein can act independently 
of the EGFR through the PLCǄ1 (Crusius et al., 1999) and on MAPKs (ERK1/2 and p38) 
activities, when the cells are placed under stress conditions (Crusius et al., 2000). On the 
other hand, E5 is also able to induce the expression of other type of receptors like the EP4 
subtype of prostaglandin E2 receptor, which increases the colony-forming efficiency and the 
Vascular Endothelial Growth Factor (VEGF) secretion in cervical cancer cells, both of which 
are required for tumor growth, angiogenesis and metastasis (Oh et al., 2009). 
 
Fig. 2. Important functions of HPV16 E5 in the cell. E5 can modify the half-life of the EGFR 
through binding with the protonic ATPase-16 kDa subunit, avoiding acidification of 
endosomes and favoring the recycling of receptors and perturbing the endocytic trafficking. 
E5 targets molecular components of the MAPKs cascade that have incidence on the 
progression of the cell cycle. E5 decreases the level of the CDK inhibitor p21Waf1 and 
modulates p27Kip1 protein levels allowing deregulation of the cell cycle, by increasing the S-
phase of the cell cycle and promoting cellular transformation. 
Other important activity observed for E5 proteins is the ability to keep the major 
histocompatibility complex (MHC) class I in Golgi, preventing its transport to the cell 
surface. In the case of HPV16 E5, this blockage is rescued by treatment with interferon. 
Unlike BPV E5, HPV16 E5 does not affect the synthesis of HLA class I heavy chains, but 
rather interferes with the transporter associated with antigen processing (TAP). The absence 
of cell surface HLA class I molecules in E5 expressing cells may allow the HPV to establish 
an infection by avoiding immune clearance of virus-infected cells by CTLs (Araibi et al., 
2004; Ashrafi et al., 2005; Marchetti  et al., 2002, 2006). In this context, Gill and coworkers 
(1998) observed that women with increasingly severe HPV16-associated lesions have 
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decreasing T cell HPV16 E5-specific proliferative responses. At the same time, HPV16 E5 
impairs TRAIL- and FasL-mediated apoptosis in HaCat cells possibly as a mechanism to 
escape immune surveillance that otherwise would be likely to detect infected cells at an 
early stage in the viral life cycle (Kabsch et al., 2004). 
Finally, the close association of E5 with growth factors and their receptors, and the fact that 
the E5 ORF is lost in cervical carcinoma cells, suggest that E5 may play a critical role in the 
genesis of cervical cancer as an initiator of the transformation process, as it has been shown 
to happen with the Ras oncoprotein in colorectal cancer (Gryfe et al., 1997; Takami et al., 
1995). Additionally, these findings support the idea that the E5 protein could be an early 
predictor marker of cervical cancer (Gill et al., 1998; Hsieh et al., 2000; Kell et al., 1994). 
4.2 E6 oncoprotein 
4.2.1 E6 biochemical properties 
E6 proteins from HPVs comprise molecules between 151 and 158 amino acids that are 
usually localized within the cell nucleus (Nomine et al., 2006; Rapp & Chen, 1998). It has 
been difficult to study E6 proteins because they are expressed at very low levels in HPV 
infected cells and are difficult to purify in a stable folded form as they tend to aggregate in 
complexes of misfolded molecules when over-expressed in bacteria (Nominé et al., 2001; 
Ristriani et al., 2002).  
In general, the E6 proteins contain two Cys-Xaa2-Cys-Xaa29-30-Cys-Xaa2-Cys zinc binding 
domains located at the N- and C-terminal parts of the molecule. These domains are novel 
types of zinc-binding structures characterized by αβαβ secondary structures separated by 29 
to 30 residues (Ullman et al., 1996). The E6 C-terminal domain is a DNA binding site that 
consists of 3-stranded β-sheet (S1, S2 and S3) with two short helices (H1 and H2) packed on 
one of its sides, a peripheric zinc binding site that protrudes away from the β sheet and that 
involves the long loop (L2) connecting H1 and H2 with a short C-terminal helix (H3). E6 has 
a main hydrophobic core (conserved among HPVs) between the β-sheet and helices H1 and 
H2, that it is not exposed to water in the full-length E6 protein. This part of the E6 protein 
has a mostly positive charge potential, except for a neutral area at the top of H1 and H2 
corresponding to the hydrophobic patch. Conserved amino acids are on the surface of the 
N- and C-terminal zinc binding motifs of E6 protein in all HPV species. Some may 
participate in generic functions shared by all HPVs E6 proteins like trans-activation, 
transformation, and protein-protein interactions, while others may have a structural role. In 
this sense, it seems that specific amino acids located at the hydrophilic sites in high- and 
low-risk HPVs, allow certain physicochemical characteristics which confer them the ability 
to recognize different subsets of cellular molecules. An example is the C-terminal region 
from HPV16 E6, which displays a strong positive charge at the nucleic acid binding site and 
the highest surface potential (Nominé et al., 2006).  
The HPV16 E6 full-length protein is composed of 151 amino acids (Rapp & Chen, 1998), 
with a calculated molecular weight of 18 kDa and with a bimodal half-life in SiHa cells of 30 
min and 4 h that seem to be related to E6 interactions with target proteins (Androphy et al., 
1987). HPV16 E6 protein C-terminal region has an IEP of 10.6 (IEP, Isoelectric Point) and it is 
the part of the molecule necessary for binding to p53, while the N-terminal region contains 
the binding site for E6AP (LxxφLsh motif) important for p53 degradation (Howie et al., 2009; 
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Thomas et al., 1999). These LxxφLsh motifs (where xx is a dipeptide and one of the residues 
is Asp, Glu, Asn or Gln; φ is a hydrophobic residue; s is a small amino acid; h is an amino 
acid capable of accepting hydrogen bonds) are Leucine-rich amphipathic helices and 
binding through these motifs is a conserved property of the E6 proteins from HPVs from the 
alpha genus. In this sense, the minimal segment still functional for p53 degradation 
comprises residues 1-142 and coordinates with two Zn+2 ions (Beerheide et al., 1999; Lipari 
et al., 2001) by means of conserved cysteine residues 30, 33, 63 and 66 at the N-terminal and 
residues 103, 106, 136 and 139 at the C-terminal (Nominé et al., 2001), where the loss of the 
Zn+2 at the C-terminal domain leads to loss of tertiary structure and protein aggregation (Y. 
Liu et al., 2009). Other proteins like E6AP, E6BP, IRF3, Paxilin and MCM7 are also able to 
bind E6 through these LxxφLsh motifs, interaction that appears to regulate the activity of 
different subset of proteins (J.J. Chen et al., 1998; Elston et al., 1998; Tong & Howley, 1997).  
Besides, the E6 proteins from oncogenic HPV types have a motif designated XT/SXV at their 
C-terminal motifs that mediates binding to specific domains known as PDZ (Howie et al., 
2009). The PDZ domains are approximately 90 amino acid stretches. The PDZ proteins 
known to bind E6 are hDlg1 and 4, tumor suppressor proteins (Kiyono et al., 1997; S.S. Lee 
et al., 1997), MAGI-1, -2 and -3, Membrane Associated Guanylate kinase homolog proteins 
(Thomas et al., 2001), MUPP-1 a multi PDZ protein (S.S. Lee et al., 2000), hScrib (Nakagawa 
& Huibregtse 2000) and PTPN3, both tyrosine phosphatase proteins (Jing et al., 2007). These 
proteins bind to E6 by the PDZ domain (aa 141-151) (Pim et al., 2009; Storrs & Silverstein, 
2007; Y. Zhang et al., 2007), acting as an adaptor to link the ubiquitin ligase to the target for 
ubiquitination by means of its C-terminal region (Pim et al., 2009). Moreover, differences in 
binding PDZs by different HPV E6 proteins have been associated with the pathogenicity of 
HPV types as a single amino acid substitution in this binding motif among HR-HPV E6 
proteins has a profound effect upon its binding to PDZ bearing target proteins (Thomas et 
al., 2001).  
E6 protein may be found full length and C-terminally truncated (E6*) expressed from a subset 
of spliced transcripts, differing in number depending on the HPV type (HPV16 E6 presents 4 
species, while HPV18 E6 only one). The E6* protein of HPV18 has the first 44 amino acids of 
the full-length protein and thereafter is composed by 13 unique amino acids derived from E6 
intronic sequences. One of these sequences results in an E6* protein of 7 kDa able to bind to 
E6AP, but not p53. This interference with the p53-mediated E6 degradation by E6* re-activates 
the p53-dependent growth arrest and apoptotic functions (Pim et al., 2009). In this sense, the 
presence of E6 over E6* may lead to aggressive cancers as E6* is present at low levels in Asian-
American HPV16 variant, the one detected in the most aggressive cancers, and at high levels in 
African variant, together with higher levels of p53 (Filippova et al., 2009). 
4.2.2 E6 functional properties 
The HR-HPV E6 proteins are distributed in the cytoplasm and the nucleus, and its 
expression leads to the transformation of NIH3T3 cells as well as the immortalization of 
human mammary epithelial cells (Holt et al., 1996). The first function associated to E6 
protein was its anti-apoptotic activity due to the ability to mediate the p53 degradation 
through the E6/E6AP complex, allowing the regulation of expression of proteins controlling 
the cell cycle, being the most important the CDK inhibitor p21Waf1 (Cooper et al., 2003). The 
p73 protein, homologue in structure and function to p53, also binds to E6 but its 
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degradation is not promoted by the oncoprotein (Das et al., 2003). However, in HPV18 
transformed cells there is an abrogation of p53 degradation due to the Pitx2a protein that 
binds to E6 and interferes with the E6/E6AP complex, leading to the accumulation of 
functional p53 protein (Wei, 2005). In this case, the anti-apoptotic effect of E6 is carried out 
through the interference of the p53/PUMA/Bax cascade (M. Vogt et al., 2006).  
On the other hand, E6 is able to transactivate the survivin promoter and along with E7, 
transactivate the c-IAP-2 promoter and confer resistance to apoptosis (Yuan et al., 2005). 
Isoforms of E6 regulate the extrinsic apoptosis in a concentration-dependent manner. When 
low levels of large (E6) and short E6 (E6*) proteins are expressed, the cells become resistant to 
TNF. On the other hand, with moderate and high levels of expression, there is a sensitization 
to TNF aided by the E6 protein ability to form complexes with each other. In this sense, the 
cellular response to TNF depends on the ratio of the two E6 isoforms, being high levels of large 
E6 responsible for the low response to TNF and E6* reverting the E6 effect (Filippova et al., 
2009). The resistance to TNF-mediated apoptosis is related to high levels of E6 and low levels 
of E6*. Other ways by which E6 protein regulates cell death pathways is by inhibiting the 
transactivation action of IRF3 (Ronco et al., 1998) and by inhibiting TLR9 transcription 
generating functional loss of TLR9-regulated pathways (Hasan et al., 2007). 
In contrast, the capacity of E6/E6AP-mediated p53 degradation favors the accumulation of 
genetic alterations. A possible explanation is that E6 alters molecules implicated in DNA-
repairing such as degradation of MGMT (Srivenugopal & Ali-Osman, 2002) and MCM7 
proteins, producing chromosomal abnormalities (Kühne & Banks, 1998; Kukimoto et al., 
1998). Also E6 from the HR-HPVs increases cellular telomerase activity via transcriptional 
activation of the telomerase catalytic subunit, hTERT (X. Liu et al., 2005) and degradation of 
the telomerase inhibitor NFX1-91 (Gewin et al., 2004), events that lead to reconstitution of 
telomerase activity allowing the immortalization process in the cells (J.P. Liu, 1999; 
Longworth & Laimins, 2004).  
Recent studies have demonstrated that HR-HPV E6 proteins have a PDZ-binding motif, 
which probably mediates the disruption of signal transduction where PDZ proteins are 
implicated (Watson et al., 2003). It has been reported that E6 binds PDZ proteins and 
promotes their ubiquitination and further degradation as observed for hDlg (Grm & Banks, 
2004), MUPP-1 (S.S. Lee et al., 2000; Massimi et al., 2004), h-SCRIB (Thomas et al., 2005), 
MAGI-1, -2 and -3 (Thomas et al., 2001, 2002). The MAGUK family protein MAGI-2 interacts 
with PTEN tumor suppressor (Wu et al., 2000), which inactivates IP3. Thus, PKB remains 
activated promoting cell survival and proliferation. Additionally, HPV E6 oncoprotein has 
been linked to the MAPK signaling pathway by increasing the levels of MAPK1/2, MEK 
1/2, and BRaf specially the E6 variant in amino acid 83, promoting cell proliferation by 
another pathway (Chakrabarti et al., 2004). 
Other molecules that bind E6 proteins (in some cases with its concomitant degradation) are 
the Rap GTPase-activating protein E6TP1 (Gao et al., 1999; L. Singh et al., 2003), the CDK 
inhibitor p16INK4a (Malanchi et al., 2004), the regulator of insulin signaling pathway tuberin 
(Lu et al., 2004), the regulator TRIP-Br1 for the E2F/DP1/pRb complex during cell-cycle 
(Gupta et al., 2003), the extracellular matrix Ca+2-binding protein fibulin-1 (Du et al., 2002) 
and the putative Ca+2 binding protein E6BP (J.J. Chen et al., 1995). Viral oncoproteins induce 
mislocation of select PDZ proteins allowing disruption of tight junctions and cause polarity 
defects in epithelial cells. The development of human cancers is frequently associated with a 
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failure of epithelial cells to form tight junctions and to establish proper apicobasal polarity 
and this is probably another pathway that E6 follows to disrupt the cellular system (Latorre 
et al., 2005). On the other hand, E6 interacts and promotes the degradation of NHERF-1, a 
PDZ domain containing protein leading to the activation of the PI3K/AKT signaling 
pathway (Accardi et al., 2011), and promoting cellular proliferation also by this mechanism. 
Furthermore, E6 protein participates in the up-regulation of SGLT1 promoting the glucose 
intake in tumor cells (Leiprecht et al., 2011). 
4.3 E7 oncoprotein 
4.3.1 E7 biochemical properties 
The nucleotide sequence of E7 oncogenes are highly conserved among different HPV types. 
The E7 ORF encodes for a small acidic phosphoprotein of 98 amino acids. The predicted 
molecular weight of this E7 protein is 11 kDa and 14 kDa when phosphorylated in vitro, 
characteristics that are observed in the E7 protein from HPV16 (Armstrong & Roman, 1993). 
However, the electrophoretic mobility of HPV16 E7 protein observed when analyzed by 
SDS-PAGE is approximately 17 kDa and this molecular weight is not affected by in vitro 
phosphorylation by CKII (Armstrong & Roman, 1992; Gage et al., 1990). Heck and 
coworkers (1992) showed that the anomalous behavior of the HPV16 E7 protein resides 
within the amino-terminal residues that confer a net negative charge to the protein.  
The E7 proteins of different HPV types are highly similar among them and share 3 regions 
of homology with the Adenovirus E1A protein and with the SV40 large T antigen (Fig. 3) 
(Barbosa et al., 1990; Brokaw et al., 1994). The amino-terminal portion of E7 protein contains 
the CR1 (Consensus Region 1) between amino acids 1-20 important for DNA synthesis and 
cellular transformation (Gulliver et al., 1997). The CR2 (aa 21-43) contains the binding site 
for pRb (aa 21-26), the phosphorylation sites for CKII (aa 31 and 32) and the site for binding 
the cyclin A-E2F complex (Barbosa et al., 1990; Gulliver et al., 1997; Münger et al., 1989). 
Although the C-terminal region of the HPV16 E7 (aa 44-98) does not contain an extensive 
amino acid homology with the CR3 of E1A, it consists of a metal binding domain composed 
of two CXXC motifs separated by 29 amino acids (Fig. 3) (Brokaw et al., 1994; Phelps et al., 
1988). The E7 proteins from HPV16 and 18 are able to bind Zn+2 with the CXXC motifs, sites 
that are important for dimerization and intracellular stabilization of the molecule 
(Clemmens et al., 1995). This region also contains a low affinity pRb binding site and is 
involved in the disruption of the E2F/pRb1 complex (Braspenning et al., 1998). 
Different molecular weights for E7 have been reported and suggested that the negative 
charge and the N-terminal region of the protein are related to these changes. Pulse-chase 
experiments by Smotkin and Wettstein (1987) with HPV16 were unable to detect changes in 
the E7 protein mobility in SDS-PAGE, suggesting that no other modifications were present. 
However, other groups have reported the presence of two E7 species in HPV6, 16 and 18 
(Gage et al., 1990; Greenfield et al., 1991; Sato et al., 1990; Selvey et al., 1994), but neither the 
origin or the biological significance have been explained. The presence of phosphorylated 
species of E7 can explain some of the different molecular weights, although treatment of E7 
protein with alkaline phosphatase suggests the presence of other posttranslational 
modifications (Selvey et al., 1994). Differences in cellular localization also exist for the E7 
protein, some groups have reported this protein as cytoplasmic, but others have found it in 
nucleus (Kanda et al., 1991; Sato et al., 1990; Selvey et al., 1994).  
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Fig. 3. Biochemical characteristics of HPV16 E7 protein. The HPV16 E7 protein has been 
reported with different eletrophoretical molecular weights (from 14-21 kDa), differences that 
have been partially explained by the net negative charge of the protein. E7 shares 3 
homology regions with the Adenovirus E1A protein and with the SV40 large T antigen 
denoted as CR1, 2 and 3. Mutational analysis of the E7 protein has shown that CR1 is 
important for cellular transformation; CR2 contains the high affinity binding site (LXCXE) 
for pRb and the phosphorylation sites for CKII (aa 31 and 32); CR3 contains two binding 
motifs (CXXC) for Zn+2 important for the protein stability and DNA binding.  
The HPV16 E7 is able to translocate through the nuclear pores via a non-classical Ran-
dependent pathway, independent of the main cytosolic Kap beta import receptors (Angeline 
et al., 2003), and it possesses two NLSs and one NES domains to shuttle between nucleus 
and cytoplasm (Knapp et al., 2009). Recently, our group identified 3 isoforms of E7 from 
HPV16 present in CasKi cells, E7a1 (17.5 kDa and IEP of 4.68), E7a (17 kDa and IEP of 6.18) 
and E7b (16 kDa and IEP of 6.96). The processing of the E7 protein was followed up by 
pulse-chase experiments and found that the first isoform synthesized was a 17 kDa protein 
and after approximately 1 h, it was processed to a faster moving band of 16 kDa with a short 
half-life (Valdovinos-Torres et al., 2008). A broad phosphorylated band of a calculated 
molecular weight of 17.5 kDa was also identified, and this could be the 17 kDa protein that 
due to the change in charge because phosphorylation is retarded in the SDS-PAGE. 
However, the lower molecular weight band of 16 kDa could not be explained by 
phosphorylation and it is suggested that an unidentified posttranslational modification 
could exist and generated the E7b isoform (Valdovinos-Torres et al., 2008). Until now, the 
only posttranslational modification identified for E7 has been the phosphorylation. 
However, immunofluorescence experiments in our laboratory have shown that a fraction of 
E7 is present in ER and Golgi apparatus (Fig. 4 and Valdovinos-Torres et al., 2008). This 
suggests that during the processing and transit of E7 through the different cell 
compartments, the protein could be posttranslationally modified.  
According with the amino acid sequence of the HPV16 E7 protein, it contains putative 
posttranslational modification sites such as the Asp 29 that can be glycosylated, or modified 
by sulphation at Tyr 23 and 26, and phosphorylated in four other residues apart from the 
already known Ser residues 31 and 32. Until now, it is unknown if all these posttranslational 
modifications apply to E7 protein, but some of them could explain the different molecular 
weights found and their presence in different cell compartments. 
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Fig. 4. Immunolocalization of HPV16 E7 protein. Cos-7 cells were transiently transfected 
with the pcDNA-E7 plasmid and chased for different times (0, 16, 24 and 48 h). Cells were 
fixed (4% p-formaldehyde) and permeabilized with 0.2% saponine. Cell preparations were 
tested with different anti-E7 antibodies produced in our laboratory (Valdovinos-Torres et 
al., 2008). (A) Cells were tested with D11 anti-E7 monoclonal antibody and with anti-
calnexin polyclonal antibody as marker for ER. (B) Cells were tested with B4 anti-E7 
monoclonal antibody and calnexin as in A. Secondary fluorescent antibodies were anti-
rabbit IgG conjugated with Alexa 488 (green) or anti-mouse IgG conjugated with Alexa 594 
(red). Images were taken at a magnification of 1000X using Confocal Microscope. The results 
showed that E7 protein is recognized by different antibodies in different cell compartments 
as the B4 monoclonal antibody recognized the E7 protein at the ER (co-localized with 
calnexin), while the D11 monoclonal antibody recognized a different isoform of E7 as no co-
localization with calnexin was observed. 
4.3.2 E7 functional properties 
The E7 proteins are the major oncoproteins of HPVs that do not have known intrinsic 
enzymatic activities. Expression of HR-HPVs E6 and E7 genes in primary human  
keratinocytes is necessary for immortalization (Hawley-Nelson et al., 1989; Münger et al., 
1989). The HPV16 E7 gene encodes a multifunctional oncoprotein that can subvert multiple 
cellular regulatory pathways. Studies on mucosal HPV types showed that E7 deregulates 
the cell cycle mainly by binding to and promoting degradation of the tumor suppressor pRb 
protein (Caldeira et al., 2005; Collins et al., 2005), resulting in the dissociation of pRb from 
E2F transcription factors and the premature cell progression into the S-phase of the cell 
cycle. This activity is mediated by the LXCXE motif and the CR3 zinc binding domain of the 
E7 protein (Singh et al., 2005). However, E7 from HR-HPVs can also bind E2F1 and activates 
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E2F1-driven transcription independent of pRb (Hwang et al., 2002). It has been postulated 
that E7 binds and activates µ-calpain (Darnell et al., 2007) to target pRb, that in turn is 
poliubiquitinated by cullin 2 (Huh et al., 2007) and degraded by the 26S proteasome through 
the interaction of E7 with the subunit 4 of the proteasome (Berezutskaya & Bagchi, 1997). In 
a similar way, E7 affects the pRb-related pocket proteins p107, p130 (Davies et al., 1993; B. 
Zhang et al., 2006) and the retinoblastoma protein associated factor p600 (Huh et al., 2005). 
However, cells try to defend themselves from the HPV infection through the expression or 
activation of molecules such as the transglutaminase 2 that inhibits pRb binding to HPV18 
E7, by incorporating polyamine (J.H. Jeon et al., 2003) and PAI-2, and regulating ARF 
protein expression, which in turn protects pRb from the accelerated degradation mediated 
by E7 (Darnell et al., 2003). At the same time, the E7 oncoprotein is able to modulate the 
G2/M phase of the cell cycle by regulating the kinase of the histone H1 through a complex 
with the p107 protein, effect that allows progression of the viral cycle (Davies et al., 1993). It 
has also been shown that HPV16 E7 associates mainly with the cyclin A-E2F complex, or to 
cyclin E retaining their CDK2-associated kinase activity (Ghittoni et al., 2010; He et al., 2003). 
On the contrary, E7 inhibits the activity of CDK inhibitors p21Waf1 (Funk et al., 1997; Jones et 
al., 1997), p27Kip1 (Zerfass et al., 1996) and indirectly the p16INK4a (Giarrè et al., 2001). The 
regulation of all these cell cycle proteins by E7 may allow the activation of a subset of 
substrates important for the completion of the viral life cycle. 
Apart from the already described E7-protein interactions, there are other groups of E7-target 
proteins that allow the modification of several different pathways such as metabolism, 
metastasis, transcription, apoptosis among others, and these subsets of E7-target proteins 
have been summarized in Table 1.  
Finally, E7 has evolved to escape the immune-response by interfering with cytokines 
signaling pathways: abrogates the immune surveillance by binding to IRF-1 and preventing 
activation of the INFǂ and ǃ promoters (Barnard & McMillan, 1999; Park et al., 2000), as well 
as represses the TGF-ǃ2 promoter by releasing E2F from pRb (Lee et al., 2002b; Murvai et al., 
2004). The cytotoxic response against HPV is also evaded by E7 through the down-
regulation of TAP1, a key protein for peptide transportation from cytosol into the ER, 
reducing MHC I-dependent antigen presentation, impairing in this way a specific CTL 
response (Vambutas et al., 2001).  
Cellular differentiation–dependent HPV life cycle has been difficult to study due to the lack 
of an in vitro culture system to differentiate epithelial cells efficiently. The recently 
development of xenographs and raft cultures have allowed the replication of HPV under in 
vitro conditions (Chow & Broker, 1997). And now, it is important that the activity of the 
oncogenic viral proteins be examined in their proper physiological contexts with complete 
viral genomes rather than relying on over-expression assays in different cell types. 
5. Proteomics and genomics in the study of HPV  
Recent advances in proteomics and genomics have allowed the study of modifications of 
profiles of cellular proteins and gene transcripts involved in a particular phenomenon 
compared to a normal status. In this way, Lee and coworkers (2004) identified a group of 
modulators regulated by E7 oncogene using proteomics and genomics technology. By using 
MALDI-TOF MS, 47 spots were identified in a HPV-negative cervical cancer cell line (C33A) 
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stably transfected with HPV16 E7. Proteins like disulfide isomerase A3, integrase interactor 
1 protein, glutathione S-transferase P and vav proto-oncogene were down-regulated, 
whereas HSP60, Ku70 binding protein, 26S proteosome subunit were up-regulated. In the 
genomic approach using DNA microarrays the researchers showed that IL-12Rǃ, 









ǂ-glucosidase Zwerschke et al.,1999, 2000 
2) Metastasis suppressors 
Nm23-H1 
Nm23-H2 
Mileo et al., 2006 
3) Transcription factors 
TBP 
TAF-110 




p48 from ISGF3 complex 
Massimi et al., 1996 
Mazzarelli et al., 1995 
Antinore et al., 1996 
Lüscher-Firzlaff et al., 1999 
D.K. Lee et al., 2002b 
Y.W. Wang et al., 2007 










Avvakumov et al., 2003 
Campo-Fernández et al., 2007 
Prathapam et al., 2001 
Park et al., 2000 
Baldwin et al., 2006 
Bernat et al., 2003 
Enzenauer et al., 1998 
5) Transcriptional 
repressors 
E2F6 McLaughlin-Drubin et al., 2008 
6) DNA modifying 
enzymes 
DNMT1 
BRG-1 from SW1/SNF 
complex 
Burgers et al., 2007 
D. Lee et al., 2002a 
7) Histone-related Mi2ǃ from NURD complex Brehm et al., 1999 
8) Tumor suppressor 
BRCA1 
hTid1-TNF-ǂ modulator 
Y. Zhang et al., 2005b 
Schilling et al., 1998 
9) Senescence regulators 
DEK 
PML 
Wise-Draper et al., 2005 
Bischof et al., 2005 





Pim et al., 2005 
Severino et al., 2007 




IkB kinase complex 
F-actin 
Vambutas et al., 2001 
Nguyen et al., 2007 
Spitkovsky et al., 2002 
Rey et al., 2000 
Table 1. Subsets of E7-target proteins according to activity pathways.  
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On the other hand, Yim and coworkers (2004b) analyzed the genomic and proteomic 
expression patterns in 2 different HPV16 E6 transfected human carcinoma cell lines. They 
reported that among 1024 known genes and expressed sequence tags (ESTs) tested by cDNA 
microarray and by performing two dimensional gel electrophoresis and MALDI-TOF-MS, 
the authors found that only the genes and proteins of CDK5, Bak, and I-TRAF matched in 
both systems, the cDNA microarray and the proteomics. In addition, proteomic profiling of 
altered proteins by anti-cancer drugs on cervical cancer cells may contribute to provide the 
fundamental resources for investigation of disease-specific target proteins, elucidation of the 
novel mechanisms of action and development of new drugs (Yim & Park, 2006) as it has 
been analyzed with the 5-fluorouracil (5FU) drug (Yim et al.,  2004a).  
Other study with a genomic approach carried on by Garner-Hamrick and coworkers (2004), 
analyzed the mRNA from primary human keratinocytes infected with retroviruses that 
expressed the HPV18 E6 and E7 genes and used to generate probes for querying Affymetrix 
U95A microarrays, which contain >12,500 human gene sequences. The results showed that 
HPV18 E6/E7 expression significantly altered the expression of 1,381 genes. A large increase 
of transcripts associated with DNA and RNA metabolism was observed, with major 
increases noted for transcription factors, splicing factors and DNA replication elements, 
among others. Multiple genes associated with protein translation were down-regulated. In 
addition, major alterations were found in transcripts associated with the cell cycle and cell 
differentiation. 
This review does not include an exhaustive search of all gene transcripts or proteins which 
expression pattern is altered in each report. In Tables 2 and 3 were summarized only those 
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on p53 
stability 
E7 can modulate normal turnover of p53. No 
transcriptional consequences on p53 targets. 
Eichten et 
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binding protein-2 (IGFBP2). 
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Up-regulation of miR-363 and down-regulation of miR-







Down-regulation of CKIs (p57 and p16) and up-
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54 up- or down-regulated genes involved in DNA 
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Down-regulation thrombospondin-1, maspin and up-







Effects of E6 
gene 
knockdown
359 genes up- or down-regulated. Cell cycle: p21; 
apoptosis: CASP4, CASP6, IGFBP3; ubiquitin proteolysis 
pathway: UBE3A; differentiation: KRT4, KRT6E, KRT18; 
anti-oncogenes RECK, VEL. 
Min et al., 
2009 
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Cdc2 is the most dramatically up-
regulated protein. 
Z.G. Liu et al., 
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E5 
Early cervical cancer 
markers related to 
E5 
Both EGFR and TfR assays detected HSIL 
with very high accuracy (100% and 
96.3%, respectively). 
Keesee et al., 
2002 
E6/E7**** 
Expression levels for  
protein features 
This large-scale analysis provides a 
framework for understanding the 
cooperation between oncoproteins in 
HPV-driven carcinogenesis. 





Decreased amount of calnexin and 
increased hsp70 expression, both 
associated to MHC-I processing. 






E7 proteins of HR-HPV types are more 
reactive in cancer patients and 
discriminating between cancer and HSIL 
or LSIL patients. 
Luevano et al., 
2010 
E7 */*** Immunosurveillance
36 proteins down-regulated and 11 up-
regulated including Ku-70 binding 
protein involved in DNA metabolism 
and hsp60 KD protein 1. 
K.A. Lee et al., 
2004 
E6 */*** Protein expression 
In RKO and A539 cells: 26 up- and down-
regulated proteins. Only three proteins 
matched with its corresponding gene: 
CDK5, Bak and I-TRAF. 






Two down-regulated proteins: actin and 
leukocyte elastase inhibitor and 26 
proteins up-regulated, amongst these: 
catalase and peroxiredoxin.





by E6, E7 or E6/E7 
Annexin III, gp96, transaldolase 1, 
elongation factor 1, proteasome 26S were 
up-regulated and have been confirmed at 
the transcriptional level. 
Ciotti et al., 
2009 
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E7 induces higher resistance to ROS-
induced cell injury, probably via the 
modulation anti-oxidant enzymes, 
including catalase and peroxiredoxin. 






Anti-cancer effect of 
5-fluorouracil 
treatment 
22 proteins up-regulated (CIDE-B, 
caspase-3, caspase-8, Apo-1/CD95 (Fas) 
and 12 proteins down-regulated (BUB3, 
c-myc protein, src substrate cortactin, 
transforming protein p21A, among 
others). 
Yim & Park 
2006; Yim et 
al.,  2004a 
E6/E7 
*/*** 
Anti-cancer effect of 
paclitaxel treatment
Paclitaxel showed anti- proliferative 
activity through the (DR)-mediated 
apoptotic pathway with TRAIL-
dependent caspase-8 activation and the 
mitochondrial-mediated pathway with 
down-regulation of bcl-2 by cytochrome 
c release. 
K.H. Lee et al., 
2005; Yim & 
Park 2006 
Used systems: * 2-DE: two-dimensional electrophoresis; ** nanoESI-MS: nanoelectrospray ionization 
mass spectrometry; *** MALDI-TOF-MS: matrix-assisted laser desorption/ionization time of flight mass 
spectrometry; ****2D-DIGE: two-dimensional difference gel electrophoresis. 
Table 3. Proteomics in HPV research. 
Working with genomics and proteomics is a great challenge as the following issues must be 
overcome: 1) The use of a standard genomic chip or an appropriate cell line has not been 
achieved, leading to results not easily comparable between different laboratories; 2) Many 
genes can be down-regulated or up-regulated during transcriptional profile analysis of a 
particular phenomenon, but this may not correspond necessarily at all with the proteomic 
profile; 3) Only a lesser number of proteins actually are modified as consequence of an 
alteration in the expression of the related gene; 4) Changes in gene expression may predict 
changes in protein expression, but not necessarily changes in functionality that in most cases 
is related to protein posttranslational modifications; 5) There are many human genes in data 
banks that codify for hypothetical proteins which activity or function are not yet known. 
Therefore, the expression of selected genes needs to be confirmed by means of other kind of 
procedures like real-time RT-PCR and the corresponding protein analysis by Western blot or 
in functional assays. In this regard, only two reports showed that some of the proteins 
studied with altered gene expression matched with the altered protein expression levels 
(Ciotti et al., 2009; Yim et al., 2004b). More remains to be done in genomics and proteomics, 
because once all the proteins modified in their expression have been characterized, the 
researchers need to investigate the way by which the proteins interact with each other, the 
sequence in which those interactions take place, and finally to establish the mechanism 
through which cervical cancer develops. This information is of great value when anti-cancer 
drugs are assayed to attack tumor cells, because the identification of the cellular targets of 
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the drug will help to design better molecules to induce specific malignant cell death. In the 
case of HPV, these studies are focused on the research of the proteins or genes that are 
altered by the presence of HR-HPV in the cell. In this sense, the identification of a biomarker 
to design chips would be useful in high-throughput screening test for uterine cervical cancer 
(Kim et al., 2006; Steinau et al., 2005), early diagnosis and prediction of response to therapy. 
6. Conclusions 
Intense work has been done to elucidate the molecular mechanisms through which the HPV 
E5, E6 and E7 oncoproteins generate cellular transformation. At the same time, it has 
became clear that the HPV oncoproteins use and modify different signal pathways, specially 
those related to cell growth, differentiation and apoptosis. The study of the transformation 
process associated to HPV has given some light about target proteins and disturbed 
mechanisms that could be considered for the design of drugs, which in the future would be 
specifically generated for the treatment of HPV associated cancers.  
Early detection remains one of the most important issues in cervical cancer research. 
Therefore, intensive screening to search for biomarkers (genes and/or proteins) particularly 
sensitive to differences between early and late stage cancer patients is the main target of the 
new technology. The development of the genomics and proteomics in cervical cancer 
associated to HPV infection will help in the identification of most accurate biomarkers for an 
automated early detection of this kind of cancer, as this approach allows the correlation of 
changes in host gene expression with the biological functions of viral genes. Although 
proteomics and genomics have simplified the analysis of a great quantity of genes or 
proteins that are modulated by the presence of HPV oncoproteins in a cell, a major concern 
has always existed as to whether the discovered biomarkers and the derived multivariate 
models are truly associated with the disease process. There is still much to do regarding to 
how these genes or its codified proteins are interconnected and which of them are actually 
important to the carcinogenic process. 
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